NK3.3-Derived Extracellular Vesicles Penetrate and Selectively Kill Treatment-Resistant Tumor Cells

Area of Science:

• Oncology
• Immunotherapy
• Cell Biology

Background:

• Cancer treatment resistance, metastasis, and relapse are significant clinical challenges.
• Therapeutic limitations include poor drug penetration into tumor tissues and the presence of cancer stem cells (CSCs).
• Extracellular vesicles (EVs) derived from natural killer (NK) cells (NK3.3EVs) have previously demonstrated cytotoxic effects against cancer cell lines.

Purpose of the Study:

• To evaluate the efficacy of NK3.3EVs in a more physiologically relevant 3D breast cancer model.
• To determine if NK3.3EVs can overcome chemoresistance in leukemia cells.
• To assess the impact of NK3.3EVs on cancer stem cell populations.

Main Methods:

• Utilized a 3D MCF7 breast cancer mammosphere model to simulate in vivo conditions.
• Generated an imatinib-resistant K562 chronic myeloid leukemia (CML) cell line for drug resistance studies.
• Assessed NK3.3EVs' cytotoxicity, apoptosis induction (caspase-3/-7 activation), and effects on CSC markers (CD34+/CD38-) and gene expression.

Main Results:

• NK3.3EVs successfully penetrated MCF7 mammospheres and induced apoptosis.
• NK3.3EVs exhibited enhanced cytotoxicity against imatinib-resistant K562 cells compared to parental cells, triggering apoptosis.
• NK3.3EVs reduced the CSC subpopulation and CSC-associated gene expression in K562 cells.

Conclusions:

• NK3.3EVs demonstrate significant therapeutic potential against resistant and stem-like cancer cells.
• NK3.3EVs show promise as an immunotherapeutic agent for challenging cancer types.
• The ability of NK3.3EVs to overcome drug resistance and target CSCs warrants further investigation.